Mira Pharmaceuticals, Inc.MIRA

MIRA Pharmaceuticals, Inc. is a clinical-stage biotech chasing ketamine derivatives and related candidates, but the numbers read like a company that’s still waiting for its first commercial act. The latest 10-Q for the quarter ending March 2026 shows net income attributable to parent at $-1.2 million, cash and cash equivalents at $4.8 million, and short-term investments at $4.6 million-leaving $9.3 million in stockholders’ equity against liabilities of just $114,761. Operating cash flow was $-1.2 million for the same period, a deficit that feels less like a crisis and more like a polite reminder that the business model isn’t yet built. (source: 10-Q, period ending 2026-03-31, https://www.sec.gov/Archives/edgar/data/1904286/000162828026006427/0001628280-26-006427-index.htm)

The company’s pipeline is where the platform story lives: SKNY-1 for obesity and addiction, Ketamir-2 for chemotherapy-induced peripheral neuropathy, and MIRA-55 somewhere in the mix. A June 17 press release announces the submission of a Phase 2a protocol for Ketamir-2, and the company also boasts worldwide rights for Ketamir-2 across 10 major markets. Yet the filing trail still shows no revenue, no commercial product, and an R&D spend of $524,781 for the quarter, a figure that’s more pocket change than powerhouse budget. The product pages and press releases are vivid, but the financial reality is still a blank canvas. (source: Press Release dated 2026-06-17, https://mirapharmaceuticals.com/press-releases/; R&D figure from 10-Q, period ending 2026-03-31, https://www.sec.gov/Archives/edgar/data/1904286/000162828026006427/0001628280-26-006427-index.htm; Pipeline pages: https://mirapharmaceuticals.com/ketamir/pipeline/ and https://mirapharmaceuticals.com/mira-55/pipeline/)

What the company does is attempt to develop and advance ketamine-derived and related drug candidates through clinical trials, with the aim of eventual commercialisation if the science and regulators cooperate. The problem is that cooperation hasn’t shown up yet in the income statement. Diluted EPS is $-0.03, the weighted average diluted share count is 19.3 million, and the balance sheet’s cash cushion is more investment portfolio than working capital. The company’s latest 8-K filings in June and July 2026 are procedural-clinical protocol submissions and rights expansions-rather than financial inflection points. (source: 10-Q, period ending 2026-03-31, https://www.sec.gov/Archives/edgar/data/1904286/000162828026006427/0001628280-26-006427-index.htm; 8-K filings: https://www.sec.gov/Archives/edgar/data/1904286/000149315226030033/form8-k.htm and https://www.sec.gov/Archives/edgar/data/1904286/000149315226032091/form8-k.htm)

The official sources for pipeline and product are the company’s own press releases and pipeline pages, which are vivid but not yet financially consequential. The SEC filings, by contrast, tell a quieter story: $9.5 million in assets, $114,761 in liabilities, and a business that’s still in the clinical spender phase rather than the revenue generator phase. The chart route for MIRA on TradingView or similar platforms will reflect the thin liquidity and low float of a micro-cap biotech, but the real action is in the filings, not the price action. (source: 10-Q, period ending 2026-03-31, https://www.sec.gov/Archives/edgar/data/1904286/000162828026006427/0001628280-26-006427-index.htm; Pipeline pages: https://mirapharmaceuticals.com/ketamir/pipeline/ and https://mirapharmaceuticals.com/mira-55/pipeline/)

What remains unproven is whether any of the pipeline candidates will clear Phase 2a, secure regulatory nods, and translate into revenue. The company’s cash runway is underwritten by short-term investments and a modest equity base, not by product sales. Until a candidate shows efficacy and regulatory approval, the business remains a clinical-stage bet dressed in the optics of a pipeline. The evidence trail is clear: the filings show the company’s present state, while the press releases show the promise. (source: 10-Q, period ending 2026-03-31, https://www.sec.gov/Archives/edgar/data/1904286/000162828026006427/0001628280-26-006427-index.htm; Press Releases: https://mirapharmaceuticals.com/press-releases/)

Next evidence the file needs: a Phase 2a readout for Ketamir-2, an FDA decision or guidance, or any revenue line in the 10-Q. Until then, the platform story is still ahead of the balance sheet. (source: Press Release dated 2026-06-17, https://mirapharmaceuticals.com/press-releases/)